PHAPI2: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: ANP32B

NCBI ID: G10541

ANP32B

PHAPI2: A Potential Drug Target and Biomarker for Neurological Disorders

ANP32B (PHAPI2) is a protein that is expressed in the brain and has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. It is also a potential drug target (or biomarker) for the treatment of these disorders.

PHAPI2 is a member of the PHA-associated protein (PAP) family, which includes a variety of proteins that are involved in the regulation of intracellular signaling pathways. These proteins are characterized by the presence of a PHA-like domain (PHAD) and by the ability to interact with various signaling molecules, including G protein-coupled receptors (GPCRs).

PHAPI2 is expressed in the brain and is involved in the development and progression of various neurological disorders, including Alzheimer's disease. This is because it is involved in the regulation of the production and degradation of a variety of proteins, including amyloid beta (Abeta), a hallmark protein that is abnormally highly concentrated in the brains of Alzheimer's patients.

PHAPI2 is also involved in the regulation of the dynamics of the neurotransmitter dopamine, which is a key signaling molecule in the brain. It has been shown to play a role in the regulation of dopamine release and uptake, and to contribute to the development of neurodegeneration in various disorders.

As a potential drug target, PHAPI2 is of interest because of its involvement in the regulation of intracellular signaling pathways that are involved in the development and progression of neurological disorders. This makes it a potential target for the development of new treatments for these disorders.

In addition to its potential as a drug target, PHAPI2 is also a potential biomarker for the diagnosis and monitoring of these disorders. This is because its expression is involved in the regulation of the production and degradation of a variety of proteins, which can be used as targets for diagnostic tests or as biomarkers for monitoring the progress of disease.

Overall, PHAPI2 is a protein that is of interest as a potential drug target (or biomarker) for the treatment of neurological disorders, including Alzheimer's disease. Further research is needed to fully understand its role in these disorders and to develop effective treatments.

Protein Name: Acidic Nuclear Phosphoprotein 32 Family Member B

Functions: Multifunctional protein that is involved in the regulation of many processes including cell proliferation, apoptosis, cell cycle progression or transcription (PubMed:20015864, PubMed:18039846). Regulates the proliferation of neuronal stem cells, differentiation of leukemic cells and progression from G1 to S phase of the cell cycle. As negative regulator of caspase-3-dependent apoptosis, may act as an antagonist of ANP32A in regulating tissue homeostasis (PubMed:20015864). Exhibits histone chaperone properties, able to recruit histones to certain promoters, thus regulating the transcription of specific genes (PubMed:20538007, PubMed:18039846). Also plays an essential role in the nucleocytoplasmic transport of specific mRNAs via the uncommon nuclear mRNA export receptor XPO1/CRM1 (PubMed:17178712). Participates in the regulation of adequate adaptive immune responses by acting on mRNA expression and cell proliferation (By similarity)

The "ANP32B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANP32B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets